Compare Bristol-Myers Squibb Co (BMY) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Monolithic Power Systems Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Monolithic Power Systems Inc trades at $1,390 (market cap $67.62B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | MPWR | |
|---|---|---|
Market Cap | $116.30B | $67.62B |
Sector | Health | Utilities |
52-Week High | $62.37 | $1.69K |
52-Week Low | $42.60 | $711.24 |
Enterprise Value | $152.24B | $66.28B |
Dividend Yield | 4.42% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Monolithic Power Systems (MPWR) trades at $1,291.38, down 4.54% on the day, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with 22.98% net income margin and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with 88% buy ratings and a $1,760 price target, representing significant upside potential from current levels.
The stock presents a compelling growth opportunity driven by AI infrastructure demand and power semiconductor trends, though elevated valuation multiples and ongoing legal investigations pose risks. Technical indicators suggest near-term weakness, but strong institutional support and consistent earnings performance support the long-term bullish case for investors seeking exposure to semiconductor growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
